
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 11.000 | 11.000 | 0.000 |
Shares | 94.080 | 94.080 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 41.445 | 22.347 |
Price to Book | 3.196 | 2.714 |
Price to Sales | 5.120 | 3.330 |
Price to Cash Flow | 25.014 | 16.400 |
Dividend Yield | 0.156 | 2.102 |
5 Years Earnings Growth | 4.010 | 6.822 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.970 | 97.797 |
Basic Materials | 0.010 | 0.472 |
Industrials | 0.010 | 0.563 |
Technology | 0.010 | 0.380 |
Number of long holdings: 91
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Beigene | CNE100005XT6 | 9.58 | 231.00 | -4.15% | |
Jiangsu Hengrui | CNE0000014W7 | 9.10 | 54.50 | -1.98% | |
InnoCare Pharma | CNE100005P56 | 9.04 | 22.45 | -3.90% | |
Dizal Jiangsu Pharmaceutical | CNE1000055W8 | 7.04 | 54.72 | -1.94% | |
Shouyao Holdings Beijing | CNE1000062V6 | 6.32 | 34.74 | -2.14% | |
Sichuan Biokin Pharmaceutical | CNE100006FN4 | 5.84 | 268.69 | -3.35% | |
Gan Lee Pharmaceuticals | CNE100003ZH1 | 5.61 | 50.52 | +0.84% | |
RemeGen | CNE100005B03 | 5.51 | 57.83 | +2.08% | |
Suzhou Zelgen Biopharma | CNE100003RP1 | 5.00 | 96.12 | -2.91% | |
Hinova Pharmaceuticals | CNE1000059F5 | 4.52 | 54.52 | +0.33% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Penghua Jiangxin Sele Alloc C | 7.3B | 0.79 | -4.29 | - | ||
Penghua HK Bank Index LOF | 4.59B | 10.60 | 14.20 | - | ||
Penghua CSI Guofang Idx Classified | 3.74B | -2.89 | -5.57 | -5.73 | ||
Penghua HongKang mix A | 2.97B | 0.37 | 2.70 | - | ||
Penghua HongKang mix C | 2.97B | 0.33 | 2.60 | - |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review